Last reviewed · How we verify

Solaraze 3% Topical Gel

Encube Ethicals Pvt. Ltd. · Phase 3 active Small molecule

Solaraze 3% Topical Gel is a topical gel formulation of tazarotene, a retinoid that modulates the expression of genes involved in cell proliferation and differentiation.

Solaraze 3% Topical Gel is a topical gel formulation of tazarotene, a retinoid that modulates the expression of genes involved in cell proliferation and differentiation. Used for Moderate to severe plaque psoriasis.

At a glance

Generic nameSolaraze 3% Topical Gel
SponsorEncube Ethicals Pvt. Ltd.
Drug classretinoid
Targetretinoic acid receptors
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Tazarotene works by binding to retinoic acid receptors, which are transcription factors that regulate the expression of genes involved in cell growth and differentiation. This leads to an inhibition of cell proliferation and an induction of cell differentiation, resulting in a reduction in the severity of psoriasis symptoms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: